Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug

Journal of Controlled Release

Volumn 133, Issue 1, 2009, Pages 77-84

  Nassar, Taher ^a   Rom, Alona ^a   Nyska, Abraham ^b   Benita, Simon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bioavailability; Nanocapsules; Oral absorption; P gp; Tacrolimus

Indexed keywords

ABSORPTION; BIOCHEMISTRY; DRYING; ENCAPSULATION; GLYCOPROTEINS; POLYMERS; PUMPS; RATS; SPRAY DRYING; SUBSTRATES;

BIOAVAILABILITY; COMMERCIAL PRODUCTS; EFFLUX PUMPS; ENTEROCYTES; HYDROXYPROPYLMETHYL CELLULOSES; NANOCARRIERS; NEW CONCEPTS; OIL CORES; ORAL ABSORPTION; ORAL ABSORPTIONS; ORAL BIOAVAILABILITIES; P-GP; PHYSIOLOGICAL ACTIVITIES; SPRAY DRYING TECHNIQUES; TACROLIMUS;

NANOCAPSULES;

EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE; NANOCAPSULE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG FORMULATION; HISTOPATHOLOGY; INTESTINE CELL; MALE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPRAY DRYING; SWINE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; ENTEROCYTES; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINES; METHYLCELLULOSE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; NANOCAPSULES; P-GLYCOPROTEIN; PARTICLE SIZE; PLANT OILS; POLYMETHACRYLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; SWINE; TACROLIMUS;

EID: 57049168640     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.08.021     Document Type: Article

References (27)

1. Knight B., Troutman M., and Thakker D.R. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge. Curr. Opin. Pharmacol. 6 (2006) 528-532
2. Wacher V.J., Salphati L., and Benet L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 20 (1996) 99-112
3. Hennessy M., and Spiers J.P. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Res. 55 (2007) 1-15
4. Foger F., Hoyer H., Kafedjiiski K., Thaurer M., and Bernkop-Schnurch A. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27 (2006) 5855-5860
5. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug. Metab. Rev. 34 (2002) 47-54
6. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., and Sugiyama Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug. Metab. Dispos. 7 (2007) 1142-1148
7. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends. Pharmacol. Sci. 1 (2006) 17-24
8. Win K.Y., and Feng S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26 (2005) 2713-2722
9. Cooper C.L., van Heeswijk R.P., Gallicano K., and Cameron D.W. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 12 (2003) 1585-1592
10. Gerrard G., Payne E., Baker R.J., Jones D.T., Potter M., and Prentice H.G. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukaemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89 (2004) 782-790
11. Constantinides P.P., and Wasan K.M. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J. Pharm. Sci. 96 (2007) 235-248
12. Risovic V., Boyd M., Choo E., and Wasan K.M. Effects of various lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob. Agents. Chemother. 47 (2003) 3339-3342
13. Nassar T., Rom A., Nyska A., and Benita S. A novel nanocapsule based delivery system approach to enhance intestinal transport and absorption of lipophilic P-glycoprotein substrate drugs. Pharm. Res. 25 (2008) 2019-2029
14. Kaplan B., Lown K., Craig R., Abecassis M., Kaufman D., Lebanthal J., Stuart F., Meier-Kriesche H.U., and Fryer J. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient. Transplantation 67 (1999) 333-338
15. Yokogawa K., Takahashi M., Tamai I., Konishi H., Nomura M., Moritani S., Miyamoto K., and Tsuji A. P-Glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm. Res. 16 (1999) 1213-1218
16. Saitoh H., Saikachi Y., Kobayashi M., Yamguchi M., Oda M., Yuhki Y., Achiwa K., Tadano K., Takahashi Y., and Aungst B.J. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur. J. Pharm. Sci. 28 (2006) 34-42
17. Uno T., Kazui T., Suzuki Y., Hashimoto H., Suzuki K., and Muhammad B.A. Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. Lipids 34 (1999) 249-254
18. Tamura S., Ohike A., Ibuki R., Amidon G.L., and Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 91 (2002) 719-729
19. Kagayama A., Tanimoto S., Fujisaki J., Kaibara A., Ohara K., Iwasaki K., Hirano Y., and Hata T. Oral absorption of FK506 in rats. Pharm. Res. 10 (1993) 1446-1450
20. Kuppens I., Breedveld P., Beijnen J.H., and Schellens J.H.M. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Investig. 23 (2005) 443-464
21. Cervelli M.J., and Russ G.R. Itraconazole-tacrolimus drug interaction. Ther. Drug. Monit. 25 (2003) 483-486
22. Gray J.E., Weaver R.N., Sinkula A.A., Schurr P.E., and Moran J. Drug-induced enteropathy characterized by lipid in macrophages. Toxicol. Appl. Pharm. 27 (1974) 145-157
23. Lown K.S., Mayo R., Leichtman A., Hsiao H., Turgeon D., Schmiedlin-Ren P., Brown M., Guo W., Rossi S., and Benet L. Role of intestinal p-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62 (1997) 248-260
24. Lown K.S., Kolars J.C., Thummel K.E., Barnett J.L., Kunze K.L., Wrighton S.A., and Watkins P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug. Metab. Dispos. 22 (1994) 947-955
25. Masuda S., Uemoto S., Hashida T., Inomata Y., Tanaka K., and Inui K. Effects of intestinal p-glycoprotein on daily tacrolimus through level in a living-donor small bowel recipient. Clin. Pharmacol. Ther. 68 (2000) 98-103
26. Hellriegel E.T., Bjornson T.D., and Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications of bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60 (1996) 601-607
27. Saad A.H., DePestel D.D., and Carver P.L. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26 (2006) 1730-1744